FDA approves new HIV combination therapy designed to reduce side effects
Source: Gilead Sciences
A new HIV combination therapy for the treatment of adults and children aged over 12 years has been approved in the United States by the US Food and Drug Administration (FDA).
The fixed-dose tablet contains a combination of elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide and is marketed in the United States as Genvoya.
The tablet includes a new form of tenofovir designed to reduce the drug’s side effects: it offers lower levels of the drug in the patient’s bloodstream compared with tenofovir disoproxil but higher levels in the cells where HIV-1 replicates. The combination therapy, which provides patients with a single daily treatment, is associated with less kidney toxicity and decreases in bone density than previously approved tenofovir-containing regimens, the FDA says.
The drug is restricted to children who weigh at least 35kg who have never taken an HIV therapy or adults whose HIV infection is suppressed. It is not recommended for patients with severe renal impairment.
The FDA’s decision was based on the results of four clinical trials involving 3,171 patients who were randomly given Genvoya or another FDA-approved HIV therapy. Genvoya was found to be as effective as other treatments, the FDA says.
The drug — marketed by Gilead Sciences — comes with a boxed warning as it can trigger a build-up of lactic acid in the blood and can cause severe liver problems, both of which can be fatal.
The drug received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use in September 2015. The recommendation is awaiting ratification by the European Commission.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20200033
Recommended from Pharmaceutical Press
This new edition of Dale and Appelbe's Pharmacy and Medicines Law is the definitive guide to law and ethics for pharmacy practice in the UK. It covers law and professional regulation and is firmly established as the definitive student textbook and reference work on this subject in the UK. Fully updated to include changes to pharmacy laws and regulation.£57.00Buy now
Pharmacy Registration Assessment Questions 2 features more than 400 entirely new, closed book and calculation questions. It can be used in conjunction with the previous volume or on its own. All questions are in line with current GPhC guidance, enabling you to prepare for the pharmaceutical pre-registration exam with confidence.£35.00Buy now
Pharmacy Registration Assessment Questions 3 is the third volume in a series that follows on from the previous, highly popular Pharmacy Registration Assessment Questions 2. It features more than 400 entirely new, closed book and calculation questions. It can be used in conjunction with the previous volume or on its own.£35.00Buy now
Pharmacy Registration Assessment Questions features over 400 closed book and calculation questions. With the registration exam having gone through a complete transformation in 2016, this volume has been developed around the new General Pharmaceutical Council (GPhC) guidelines.£33.00Buy now